Hologic, Inc. (NASDAQ:HOLX) has been given a consensus rating of “Buy” by the fifteen brokerages that are covering the firm, Marketbeat reports. One equities research analyst has rated the stock with a sell rating, five have given a hold rating and nine have given a buy rating to the company. The average 12-month target price among analysts that have updated their coverage on the stock in the last year is $48.55.

A number of research firms have commented on HOLX. Royal Bank Of Canada reaffirmed a “sector perform” rating and set a $45.00 price objective (down from $50.00) on shares of Hologic in a research report on Wednesday, August 9th. BidaskClub cut shares of Hologic from a “hold” rating to a “sell” rating in a research report on Wednesday, August 9th. Jefferies Group LLC set a $49.00 target price on shares of Hologic and gave the company a “buy” rating in a research report on Sunday, May 28th. Barclays PLC reissued an “equal weight” rating and issued a $51.00 target price (down previously from $53.00) on shares of Hologic in a research report on Wednesday, August 9th. Finally, Needham & Company LLC reissued a “buy” rating on shares of Hologic in a research report on Tuesday, August 1st.

Shares of Hologic (NASDAQ:HOLX) opened at 37.42 on Friday. The company’s 50-day moving average is $42.62 and its 200 day moving average is $42.82. The firm has a market capitalization of $10.50 billion, a price-to-earnings ratio of 13.94 and a beta of 0.90. Hologic has a 1-year low of $35.15 and a 1-year high of $46.80.

Hologic (NASDAQ:HOLX) last released its quarterly earnings data on Wednesday, August 2nd. The medical equipment provider reported $0.50 EPS for the quarter, topping the Zacks’ consensus estimate of $0.49 by $0.01. Hologic had a net margin of 25.65% and a return on equity of 23.18%. The firm had revenue of $806.10 million during the quarter, compared to analysts’ expectations of $799.70 million. During the same period in the previous year, the business posted $0.51 earnings per share. The company’s revenue for the quarter was up 12.4% compared to the same quarter last year. On average, analysts expect that Hologic will post $2.01 EPS for the current fiscal year.

In related news, Director Elaine Ullian sold 8,938 shares of the company’s stock in a transaction dated Friday, June 2nd. The shares were sold at an average price of $43.99, for a total transaction of $393,182.62. Following the completion of the sale, the director now owns 23,810 shares of the company’s stock, valued at $1,047,401.90. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, insider Peter J. Valenti III sold 10,005 shares of the company’s stock in a transaction dated Tuesday, May 30th. The stock was sold at an average price of $43.44, for a total transaction of $434,617.20. Following the sale, the insider now directly owns 20,994 shares of the company’s stock, valued at approximately $911,979.36. The disclosure for this sale can be found here. Insiders have sold 51,551 shares of company stock valued at $2,244,458 in the last ninety days. 0.79% of the stock is currently owned by company insiders.

A number of large investors have recently bought and sold shares of HOLX. Commonwealth Bank of Australia boosted its stake in Hologic by 31.0% in the second quarter. Commonwealth Bank of Australia now owns 2,533 shares of the medical equipment provider’s stock valued at $114,000 after buying an additional 600 shares in the last quarter. TrimTabs Asset Management LLC boosted its stake in Hologic by 88.8% in the first quarter. TrimTabs Asset Management LLC now owns 2,993 shares of the medical equipment provider’s stock valued at $127,000 after buying an additional 1,408 shares in the last quarter. Advisor Partners LLC purchased a new stake in Hologic during the first quarter valued at $201,000. National Asset Management Inc. purchased a new stake in Hologic during the second quarter valued at $203,000. Finally, Miles Capital Inc. purchased a new stake in Hologic during the first quarter valued at $206,000. 94.43% of the stock is owned by institutional investors and hedge funds.

TRADEMARK VIOLATION NOTICE: “Hologic, Inc. (HOLX) Receives Average Recommendation of “Buy” from Analysts” was first posted by American Banking News and is owned by of American Banking News. If you are reading this report on another site, it was stolen and reposted in violation of US & international copyright law. The legal version of this report can be accessed at https://www.americanbankingnews.com/2017/08/19/hologic-inc-holx-receives-average-recommendation-of-buy-from-analysts.html.

Hologic Company Profile

Hologic, Inc is a developer, manufacturer and supplier of diagnostics products, medical imaging systems and surgical products with an emphasis on women’s health. The Company operates through four segments: Diagnostics, Breast Health, GYN Surgical and Skeletal Health. The diagnostics products include Aptima family of assays, ThinPrep system, the Rapid Fetal Fibronectin Test and Procleix blood screening assays.

Analyst Recommendations for Hologic (NASDAQ:HOLX)

Receive News & Ratings for Hologic Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hologic Inc. and related companies with MarketBeat.com's FREE daily email newsletter.